

Eylea - (2mg/0.05ml; Intravitreal Injection)

| | | | |
|------------------------------|--|-----------------------------|---------------------|
| Generic Name | aflibercept | Innovator | Regeneron |
| Dosage | 2mg/0.05ml; Intravitreal Injection | Branded US Sales | More Than \$1000 mn |
| Probable FTF | None | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | None | Tentative Approvals | None |
| Final Approvals | More Than 5 | Generic Launches | None |
| Indication | EYLEA is indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD) | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.